Gut microbiota profiles of patients with idiopathic pulmonary fibrosisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared gut microbiota composition between patients with idiopathic pulmonary fibrosis (IPF) and healthy controls. They also examined whether antifibrotic drug therapy altered gut dysbiosis in IPF patients.
How was it studied?
The study included 12 IPF patients on antifibrotic drugs, 12 IPF patients without antifibrotic therapy, and 8 healthy controls. Stool DNA underwent 16S ribosomal RNA gene sequencing across the V1-V9 hypervariable regions.
What did they find?
Campylobacterota appeared only in IPF groups, while Staphylococcales and Gemellaceae appeared only in controls. IPF groups showed lower Actinobacteria, Bifidobacteriales, Burkholderiales, Bacteroidaceae, Dorea, Fusicatenibacter, and Ruminococcus gauvreauii, and higher Enterobacterales, Erysipelotrichaceae, Holdemanella, and Alloprevotella than controls. Comparing IPF patients on versus off antifibrotic drugs, only Lachnospiraceae UCG 004 differed, being lower in the treated group.
Why it matters
Distinct gut taxa shifts in IPF patients suggest gut microbiota dysbiosis may relate to disease pathogenesis. Tracking microbiota changes during antifibrotic treatment could help guide clinical management of adverse effects.